Tilray Imports Bulk Supply of Medical Cannabis Oil Into The United Kingdom

CANADA: Tilray, a global pioneer in cannabis research, cultivation, production and distribution, today announced it has imported medical cannabis oral solutions in bulk into the United Kingdom from its Good Manufacturing Practices (GMP)-certified facility in Canada. This export allows Tilray to provide authorized U.K. patients in need with a locally maintained supply of medical cannabis oral solutions.
 
In September 2018, Tilray announced the successful import of Tilray 2:100 medical cannabis oil for a pediatric patient in need in the United Kingdom. Tilray’s 2:100 cannabis oil was supplied via a government-approved special access program following the U.K. Home Secretary’s historic announcement that declared prescriptions of cannabis-derived medicines legal for patients with an exceptional clinical need.
 
“As demand ramps up in the U.K., Tilray is well positioned to be a leading supplier of medical cannabis products,” says Sascha Mielcarek, Managing Director of Tilray Europe. “Regulations are progressing as more and more countries across Europe are recognizing the benefits of medical cannabis and its potential to improve patients’ quality of life. We’re pleased to reaffirm our commitment to delivering medical cannabis to patients in the U.K. and look forward to offering a variety of GMP-certified, pharmaceutical-grade products in the coming months.”
 
Tilray has six medical cannabis products approved for medical use in the U.K. that can be made available to patients with medical cannabis prescriptions obtained through private practice or the National Health Service. Tilray anticipates supplying a variety of cannabidiol (CBD)-dominant, tetrahydrocannabinol (THC)-dominant and balanced oral solutions for patients looking to use medicines derived from cannabis.
 
“This bulk import of Tilray medical cannabis oral solutions provides patients in need access to a sustained supply of GMP-certified, high quality medical cannabis,” says Catherine Jacobson, Tilray’s Vice President of Medical and Regulatory Affairs. “This is an important step in improving access in the U.K. Tilray will continue to advocate for reasonable patient access to medical cannabis in the U.K. and countries around the world.”

Cura Partners Enters European Market With Plata Wellness To Distribute Select CBD Brand

UNITED KINGDOM: Cura Partners, one of the largest cannabis and hemp-based CBD consumer products companies in the world, is officially entering the European market (EU) through a distribution agreement with Plata Wellness.

CuraThe agreement allows Cura’s Select CBD products to be available direct to consumers in legal markets across Europe via the website www.selectcbd.eu. Cura has appointed Plata Wellness Limited (Plata) to assist with its entry into the EU. In addition to Plata’s role as Cura’s inaugural overseas distributor, Plata is also providing a number of other services including order fulfillment, payment processing, and in the future, licensing and manufacturing. This partnership begins with the introductions of Select’s CBD disposable vaporizer cartridges but will, over time, add other legal consumer products including tinctures, gel caps and muscle rubs.

“Cura’s decision to move into Europe is in direct alignment with the company’s mission to be the leading provider of cannabis oil to consumers and brands in legal U.S. and international markets,” said President and Chief Executive Officer Cameron Forni. “I’m proud of the team that made this possible, and look forward to partnering with Plata Wellness to get the Select CBD brand into the hands of consumers across Europe.”

Europe is home to more than 741 million people, more than double the combined population of the United States and Canada. When trying to extrapolate these numbers to account for the potential demand in Europe’s much larger population, there is a crystal-clear reason why established cannabis companies in the United States are now turning their attention to Europe.

“We are delighted to have partnered with Cura, the market leading company in this sector. We are excited to work together to bring the Select brand to prominence in Europe and to supply consumers with these award-winning products,” said Jon Robson, Managing Director at Plata Wellness Limited.

Consumers in the United Kingdom can purchase Select CBD Blends vape pens online at www.selectcbd.eu with additional products coming soon.

Study: Cannabis Inhalation Not Associated With COPD, Other Tobacco-Related Harms

UNITED KINGDOM: Cannabis smoke exposure, even long-term, is not positively associated with chronic obstructive pulmonary disease (COPD), lung cancer, or irreversible airway damage, according to a literature review published in the journal Breathe.

Tilray Exports 2:100 CBD Oil To The United Kingdom

CANADA: Tilray, a global leader in cannabis research, production and distribution, announced today that Tilray 2:100, a product produced at Tilray’s federally licensed, Good Manufacturing Practice (GMP)-certified facility in Canada, was successfully imported into the United Kingdom, to supply a pediatric patient in need.  
 
The changing regulatory measures in the United Kingdom (UK) previously prohibited the use of medical cannabis. However, in July 2018, Home Secretary Sajid Javid announcedthat clinicians will now legally be able to prescribe cannabis-derived medicines to patients with an exceptional clinical need noting “recent cases involving sick children made it clear to me that our position on cannabis-related medicinal products was not satisfactory.”
 
With government-approved compassionate access, the UK-based patient suffering from a rare form of epilepsy, now has reliable access to Tilray 2:100, the product used as the primary medicine in a clinical trial testing the efficacy and tolerability of cannabis-derived medicine as treatment for pediatric epilepsy. The trial was conducted in partnership with The Hospital For Sick Children (SickKids) in Toronto, Canada and published promising results in August.
 
In a press release issued by SickKids, Dr. Blathnaid McCoy, Staff Neurologist at SickKids who conducted the clinical trial and authored the research, said “In the participants who reached the target treatment dose we saw a statistically significant reduction in motor seizures, and an increase in seizure-free days compared to those who did not reach the target dose. We observed promising clinically beneficial effects including a reduction in seizure frequency and improvements in certain aspects of adaptive functioning and quality of life measures.”
 
The Tilray oral solution imported to the United Kingdom contains 100 mg/ml cannabidiol (CBD) and 2mg/ml tetrahydrocannabinol (THC), the same ratio of active cannabinoids Tilray used in the recent clinical trial led by SickKids. This ratio of the active cannabinoids was selected after Tilray conducted extensive research on published data of cannabinoids to treat seizures. Tilray 2:100 was deemed safe and well tolerated in pediatric patients by the researchers.

Study: CBD Effective As Adjunctive Therapy For Schizophrenia

UNITED KINGDOM: The daily administration of CBD (cannabidiol) as an adjunctive therapy mitigates psychotic symptoms in patients with schizophrenia, according to clinical trial data published online ahead of print in The American Journal of Psychiatry.

British researchers assessed the adjunctive use of CBD compared to placebo over a six-week period in a randomized trial of 88 schizophrenic patients. Participants ingested 1000mg of plant-derived CBD per day in addition to their conventional medications.

Subjects in the CBD treatment group “had lower levels of positive psychotic symptoms and were more likely to have been rated as improved and as not severely unwell by the treating clinician” at the conclusion of the trial. CBD administration was also associated with “improvements in cognitive performance and in the level of overall functioning,” although these changes did not reach statistical significance.

“These findings suggest that CBD has beneficial effects in patients with schizophrenia,” authors concluded. “As CBD’s effects do not appear to depend on dopamine receptor antagonism, this agent may represent a new class of treatment for the disorder.”

Results of a prior clinical trial published in the journal Translational Psychiatry determined that CBD is superior to amisulpride, a potent anti-psychotic agent, in mitigating psychotic symptoms in schizophrenic patients.


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial,” appears in The American Journal of Psychiatry.

Study: CBD Administration Reduces Blood Pressure

UNITED KINGDOM: Oral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.

Investigators from the University of Nottingham assessed the effects of a single oral dose of 600 mg of CBD extract versus placebo in nine male subjects.

Cannabidiol administration reduced resting systolic blood pressure and stroke volume (the amount of blood pumped by the left ventricle of the heart in one contraction). Compared to placebo, CBD intake was associated with reduced BP levels following exercise and in response to stress. Increased heart rate was observed following CBD administration, but no “adverse events” were reported by participants either during or following the study sessions.

Authors concluded: “Our data show that a single dose of CBD reduces resting blood pressure and the blood pressure response to stress, particularly cold stress, and especially in the post-test periods. This may reflect the anxiolytic and analgesic effects of CBD, as well as any potential direct cardiovascular effects. … Further research is also required to establish whether CBD has any role in the treatment of cardiovascular disorders such as a hypertension.”

 

Clinical Trial: THCV Lowers Blood Sugar Levels In Type 2 Diabetics

UNITED KINGDOM: The administration of THCV (tetrahydrocannabivarin), a non-psychoactive component of cannabis, is positively associated with glycemic control in type 2 diabetics, according to the randomized, placebo-controlled data published in the journal Diabetes Care.

Investigators from the University of Nottingham, School of Medicine assessed the twice daily administration of various cannabinoids (CBD or THCV or CBD and THCV in combination) versus placebo over a period of 13 weeks in 62 non-insulin dependent subjects with type 2 diabetes.

Authors reported that the administration of THCV alone “significantly decreased fasting plasma glucose” levels and improved pancreatic cell function. By contrast, other treatment therapies failed to show detectable metabolic effects.

Investigators concluded, “THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.”

Population-based observational studies have previously reported that cannabis consumers typically possess lower BMI and other favorable indices related to diabetic control compared to those without a history of marijuana use.

Twins Study Finds No Evidence That Marijuana Lowers IQ In Teens

UNITED KINGDOM: Roughly half of Americans use marijuana at some point in their lives, and many start as teenagers. Although some studies suggest the drug could harm the maturing adolescent brain, the true risk is controversial. Now, in the first study of its kind, scientists have analyzed long-term marijuana use in teens, comparing IQ changes in twin siblings who either used or abstained from marijuana for 10 years. After taking environmental factors into account, the scientists found no measurable link between marijuana use and lower IQ.

“This is a very well-conducted study … and a welcome addition to the literature,” says Valerie Curran, a psychopharmacologist at the University College London. She and her colleagues reached “broadly the same conclusions” in a separate, non-twin study of more than2000 British teenagers, published earlier this month in the Journal of Psychopharmacology, she says. But, warning that the study has important limitations, George Patton, a psychiatric epidemiologist at the University of Melbourne in Australia, adds that it in no way proves that marijuana—particularly heavy, or chronic use —is safe for teenagers.

Most studies that linked marijuana to cognitive deficits, such as memory loss and low IQ, looked at a single “snapshot” in time, says statistician Nicholas Jackson of the University of Southern California in Los Angeles, lead author of the new work. That makes it impossible to tell which came first: drug use or poor cognitive performance. “It’s a classic chicken-egg scenario,” he says.

 

Study: High-Potency Marijuana Linked With Neural Damage

GREAT BRITAIN:  In scanning the brains of drug users, researchers at Kings College London found smokers of high-potency pot had smaller amounts of white brain matter inside their corpus callosum, a neural pathway connecting the left and right halves of the brain.

While pot smokers generally showed more damage to the corpus callosum than non-smokers, those who smoked super strong weed known as ‘skunk’ showed more significant white matter loss.

Scientists performed MRI scans on the brains of 56 patients who had visited a London hospital reporting a first episode of psychosis. The brains of 43 healthy participants were also scanned. All the participants were surveyed about their drug habits.

First Legal ‘Charlotte’s Web’ Cannabis Oil To Go On Sale In The UK

GREAT BRITAIN:  Cannabis oil has become increasingly sought after as an alternative treatment for a range of conditions including severe epilepsy, but legislators have been unwilling to legalise it due to its association with marijuana.

Thanks to the work of advocates including CNN’s Dr Sanjay Gupta – who famously reversed his stance on medical marijuana to become a staunch supporter – and documentaries such as The Culture High, the wider public and legislators have come to see CBD oil’s medical value.

UK CBD are the first British company to sell ‘Charlotte’s Web’ cannabis oil since it was made legal on 31 July. Charlotte’s Web products are derived from low THC – the major psychoactive component in marijuana – high CBD – which is not psychoactive – cannabis strains. In other words they do not induce the ‘high’ associated with recreational marijuana. These varieties of cannabis are commonly referred to as hemp.